Cargando…
Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
PI3Kδ is a key mediator of B-cell receptor signaling and plays an important role in the pathogenesis of certain hematological malignancies, such as chronic lymphocytic leukemia. Idelalisib, which targets PI3Kδ specifically, is the first approved PI3K inhibitor for cancer therapy. Recently, we carrie...
Autores principales: | Jia, Wenqing, Luo, Shuyu, Zhao, Wennan, Xu, Weiren, Zhong, Yuxu, Kong, Dexin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571382/ https://www.ncbi.nlm.nih.gov/pubmed/36234743 http://dx.doi.org/10.3390/molecules27196211 |
Ejemplares similares
-
The p110δ crystal structure uncovers mechanisms for selectivity and potency of novel PI3K inhibitors
por: Berndt, Alex, et al.
Publicado: (2010) -
The PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells
por: Patton, Daniel T., et al.
Publicado: (2011) -
Regulation of p110δ PI 3-Kinase Gene Expression
por: Kok, Klaartje, et al.
Publicado: (2009) -
Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K
por: Okkenhaug, Klaus, et al.
Publicado: (2007) -
p110δ PI3 kinase pathway: emerging roles in cancer
por: Tzenaki, Niki, et al.
Publicado: (2013)